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Background: Exhaled NO (FENO) is a useful biomarker for the monitoring of asthma control and
response to therapy. However, there is a lack of data on FENO levels and their interpretation in
Primary Care asthma population depending on their treatment and smoking habit. Besides, the
majority of current FENO tests have been done by stationary chemiluminescence analysers
whose use is limited to research laboratories.
Methods: FENO measurements by the novel hand-held NO monitoring device (NIOX MINO
) were
made in 96 asthma patients (32 males, mean age 53 12) at five local General Practices during
their scheduled 15e20 min visits for lung function assessment.
Results: Success rate was 78% and the intra-subject coefficient of variation was 8.7%. Inhaled
corticosteroid treatment had an overall reducing effect on the FENO value (30.5 [19.8e49.8])
vs. patients not on the ICS (26.5 [19e94]) (p< 0.044). FENO levels in the ICS treated current or
ex-smokers group of patients were still significantly above the normal values (p< 0.0001).
FENO levels were similar in patients receiving ICS whether there were current, ex-smokers or
non-smokers. The highest FENO levels (94 [15.8e151]) were found in asthmatic current smokers
and not receiving treatment with ICS. The most ‘‘normalised’’ FENO levels (35.3 [13.5e35.3])
were seen in ex-smokers.
Conclusions: FENO measurements performed with a new hand-held monitoring device are
reproducible and feasible in General Practice in the majority of patients of different ages
and asthma severities. A high percentage of patients with different severities of asthma and
regardless of their treatment with ICS and current smoking habit (current and/or ex-smokers)
had highly elevated FENO values, suggesting that their current therapy was possibly insufficient
to control the underlying degree of airway inflammation and asthma symptoms.
ª 2008 Elsevier Ltd. All rights reserved.irway Disease, NHLI, Imperial College, Dovehouse Street, London SW3 6LY.
rial.ac.uk (S.A. Kharitonov).
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Airway inflammation is a central process in the pathogen-
esis of asthma and other respiratory diseases. It is
increasingly recognized that the measurement of fractional
exhaled nitric oxide (FENO) is a useful non-invasive method
to assess airway inflammation.1 In asthma, FENO has been
proposed as a useful biomarker to diagnose the disease,2
to monitor the response to steroids,3,4 and asthma control,5
to verify adherence to therapy6 and to guide inhaled
corticosteroid treatment.7 However, results from clinical
trials, performed in highly selected patients where smokers
are usually excluded and only steroid-naı¨ve or patients
treated with the study medication are studied, cannot be
directly or easily implemented into day-to-day clinical
practice, especially not in Primary Care. To date, there is
a lack of data on FENO levels and their interpretation in
‘‘real life Primary Care asthma population’’, including ex-
and current smokers who are treated with different doses
of ICS and other anti-inflammatory medications.
Much of the difficulty of primary care physicians to
interpret the FENO result in routine clinical practice
descended from the limitations of our knowledge in the
impact of pharmacotherapy and smoking; the variability
in FENO levels in asthma patients who are ex- and current
smokers and are currently on ICS.
Besides, the majority of current FENO tests have been
done by stationary chemiluminescence analysers, whose
reproducibility has been well validated.8 But these devices
show several drawbacks such as high cost, the lack of user
friendliness, difficult transportability, and requirements for
frequent calibration and technical maintenance, which
limit their use to research laboratories. Recently, an
alternative technology has been developed offering advan-
tages regarding reduced cost, increased portability and pre
calibrated sensor.9 Thus, this new type of device would
promote a higher acceptance of FENO measurement method
in general healthcare and home monitoring of asthma. A
new hand-held NO monitoring device, which was designed
to adhere to established Guidelines,10 has been recently
cleared for clinical use in Europe.
The aim of our study was to estimate the feasibility and
repeatability of FENO measurements using the new hand-held
NOmonitoring device and its potential as a novel tool formon-
itoring asthma in General Practice. Secondly, we tried to shed
some light on the possibility of interpreting FENO results and of
drawing clinical conclusions on the values in current and ex-
smokers and patients who are currently on ICS.
Materials and methods
Subjects
Subjects were studied by two of our clinical research nurses
and, occasionally by a physician from the Asthma
Laboratory of the National Heart and Lung Institute, at
five local General Practices in London during the patient’s
scheduled visits for lung function assessment. Diagnosis of
asthma was made by the General Practitioner and was
based on history, asthma symptoms, variability of the peak
flow measurements and treatment with b2-agonists andinhaled corticosteroids (ICS). All patients underwent lung
function test and FENO measurement and were asked about
their smoking habits, medications, severity and frequency
of daily and night-time symptoms (chest tightness, short-
ness of breath, wheezing and cough), and atopy (previous
skin prick test results). In addition, at the time of the visit
standard reversibility was performed when necessary. Each
group of asthma symptoms was ranged between 0 (no
symptoms), 1 (mild), 2 (moderate) and 3 (severe). The total
score was a sum of the intensity of the above symptoms. We
studied an unselected group of patients. There was no pre-
selection or exclusion based on current treatment with or
without ICS or smoking habit.
The duration of the visit, including the FENO measure-
ments was between 15 and 20 min for each patient. None
of the patients had used the novel hand-held NO monitoring
device before. Depending on combination of their symp-
toms, lung function, and current maintenance treatment,
patients were classified into four groups of different
severity: intermittent, mild, moderate and severe persis-
tent asthma according to the GINA guidelines.11
All patients gave written informed consent.
Lung function
Measurement of FEV1 and FEV1/FVC was made with a dry
spirometer (Vitalograph-S; Vitalograph Ltd., Buckingham,
UK) which met American Thoracic Society (ATS) standards.
FENO measurements
FENO was measured using a new hand-held NO monitoring
device (NIOX MINO, Aerocrine AB, Sweden). Patients
were asked to inhale NO free air deeply to total lung
capacity through a filter connected to the instrument,
and to exhale slowly through the filter for 10 s. All exhala-
tions were to be performed at an exhalation pressure of
10e20 cm H2O, to maintain a fixed flow rate of 50 5 ml/s.
Any exhalation which did not meet the ATS/ERS10
requirements was not accepted by the device and the
subject had to perform a new manoeuvre. Each patient
was asked to perform two valid FENO measurements
(maximum six attempts), as we demonstrated8 and recently
have been recommended by the ATS/ERS joint statement.10
No patient had performed FENO measurements before.
Statistical methods
Data are expressed as median [25e75% percentile] unless
stated otherwise. We calculated the success rate as the
proportion of subjects succeeding in obtaining either one or
two valid FENO measurements out of a maximum of six at-
tempts in NIOX MINO. The difference regarding age and spiro-
metric data between patients able to perform themanoeuvre
and those who were unable was obtained using the Manne
Whitney non-parametric analysis. The difference between
first and second measurements was determined using the
Wilcoxon test for within group comparisons. Repeatability
of FENOmeasurements was assessedwith BlandeAltman anal-
ysis. The intra-subject coefficient of variation (CV), defined
as mean (FENO1, FENO2)/SD(FENO1, FENO2)*100, was also
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analysed using the KruskaleWallis test. Multiple stepwise
forward regression analysis was also used. Mean individual
FENO values were correlated to FEV1 (% pred) and FEV1/FVC
(%) using the Spearman rank correlation coefficient. A p value
of less than 0.05 was considered significant.
Results
Success rate of the FENO tests
A total of 96 patients were recruited (32 males, mean age
53 12). Two valid measurements were obtained in 72
patients, eight patients performed only one valid manoeu-
vre, 12 subjects (10 of them were receiving inhaled cortico-
steroids) were unable to perform the exhalation manoeuvre
and complete the NO measurement. Their age, FEV1 param-
eters and total symptom score are presented in Fig. 1. Four
subjects did not perform the FENO tests, as the NIOX MINO
was not available at the time of the measurements. Charac-
teristics of all the patients are shown in Table 1.
Patients unable (13% of the total number) to perform the
FENO test were older (62 vs. 55 years, pZ 0.03; Fig. 1,
Panel A) and had significantly lower FEV1 values (1.6
[1.2e1.9] vs. 2.4 [1.9e2.8] L, pZ 0.003; Fig. 1, Panel B)
compared to those who completed the test successfully.
Their ability to perform the FENO test was not affected by
their asthma symptoms (Fig. 1, Panel C).
Success rate was 78%, considering patients who obtained
two validmeasurements, but it reached 87%when taking into
account patients who performed at least one manoeuvre.Figure 1 Distribution of patients who were able vs. unable to com
(Panel A), FEV1 (Panel B) and asthma symptoms (Panel C).Repeatability of the FENO measurements
There was no significant difference in FENO values between
males (43 34.5 ppb) and females (41 32.3 ppb).
There was no significant difference between the 1st and
the 2nd FENO measurements in either of the studied age
groups: group 14e29 years (3.7 6.7 ppb), group 30e49
years (1.3 5.8) and group 50e84 years (0.2 6.1),
respectively. The Spearman’s correlation coefficient
between the 1st and the 2nd FENO values in all the age
groups was 0.95 (p< 0.01). The intra-subject coefficient
of variation was 8.7%.
The repeatability of FENO measurements as measured by
the BlandeAltman analysis yielded an upper limit of agree-
ment of 11.2 ppb and a lower limit of e13.2 ppb. After
removal of outliers (i.e. five measurements outside the
limits of agreement) the upper limit of agreement was
8.6 ppb and the lower limit was e9.8 ppb (Fig. 2).
Correlation of the FENO levels with lung
function, age, total symptom score
Significant, although weak, positive correlations were found
between the FENO levels and FEV1 (rZ 0.2, pZ 0.03). There
was no correlation between the FENO and FEV1/FVC ratio.
Multiple stepwise forward regression analysis to predict
an average FENO has been applied and the following param-
eters included: age, total score, FEV1 (L), FEV1 (% pred),
FEV1/FVC (%) (score 0/1), long-acting b2-agonists (0/1),
gender (0/1), and current smoking (0/1). The only signifi-
cant predictor was FEV1 (pZ 0.015).plete the standardised FENO test in accordance with their age
Table 1 Characteristics of asthma patients who underwent clinical examination at General Practice, including FENO measure-
ment with the hand-held device NIOX MINO.
All patients (nZ 96) Patients able to perform
the FENO test (nZ 80)
Patients unable to perform
the FENO test (nZ 12)
Age (years) 56 [44.5e63.5] 55 [43e61] 61.5 [54e74.5]*
Sex (M/F) 32/64 29/51 2/10
FEV1 (% pred) 86 [71e98] 86 [71e99] 76 [68e92]
FEV1/FVC (%) 73 [64e80] 74 [65e80] 72 [68e82]
ICS (yes/no) 79(82%)/17(18%) 65(81%)/15(19%) 10(83%)/2(17%)
Current smoker 21(22%) 16(20%) 5(42%)
Ex smoker 33(34%) 29(36%) 2(17%)
Non smoker 42(44%) 35(44%) 5(42%)
Data are median [25e75% percentile]; *p< 0.05; MZmale; FZ female; FEV1Z forced expiratory volume in 1 s; % predZ per cent pre-
dicted; FVCZ forced vital capacity; ICSZ inhaled corticosteroids.
1420 O. Torre et al.Effect of asthma severity and treatment
with inhaled corticosteroids on FENO
The difference in mean FENO between different asthma
severity groups was not statistically significant, except
the levels in patients with moderate persistent asthma
who were not treated with the ICS at the time of the inves-
tigation (64.5 [14e144.5] ppb) vs. moderate (31.8 [21.3e
60] ppb, pZ 0.02) and severe persistent (31 [17e49.8]
ppb, p< 0.001), asthma treated with the ICS (Fig. 3A).
There was an upward however not significant trend in
FENO values, from the intermittent (24.5 [28.8e36] ppb) to
mild persistent (24 ppb) and moderate persistent (64.5
[14e144.5] ppb) asthma patients who were not on ICS at
the time of investigation. Although FENO levels were lower
in asthma patients receiving ICS (mild 28 [17.8e79.3],
moderate 31.8 [21.3e60] and severe persistent asthma 31
[17e49.8] ppb), compared to patients not on ICS, previously
defined normal FENO levels (mean 16.3 ppb) were not
achieved. In fact, FENO levels in intermittent and moder-
ate/severe persistent asthma patients receiving ICS were
significantly (pZ 0.02, pZ 0.0003 and p< 0.0001, respec-
tively) above the normal FENO values (16 ppb).
8,12
There was a significant correlation between FENO
values and total symptom score (rZ 0.4, p< 0.05),Figure 2 Reproducibility analysis by Bland-Altman of the 1st
and the 2nd FENO measurements by NIOX MINO.although no significant relationship between the FENO
value and asthma symptoms was found when the patients
were split into the two groups according to their treat-
ment (Fig. 3B).Effect of smoking and ICS on FENO
Inhaled corticosteroid treatment had an overall reducing
effect on the FENO value (30.5 [19.8e49.8] ppb) vs. patients
not on the ICS (26.5 [19e94]) (p< 0.044) (Fig. 4, Panel A).
FENO levels in the ICS treated group of patients were still
significantly above the normal values (p< 0.0001).
Smoking habit (current and ex-smokers vs. non-smokers)
did not result in a significantly lower FENO value when all
patients were analysed together. This was true regardless
of whether the patients were on treatment with ICS or
not (non-smokers 35.5 [24e53] ppb vs. current and ex-
smokers 28.3 [16.3e49.8] ppb; Fig. 4, Panels A and B).
FENO levels of both groups remained significantly above nor-
mal values (p< 0.0001).
No significant difference in asthma symptom scores was
seen in any of the patient groups, separated by their
smoking habit and the use of ICS (Fig. 1, Panel A). Only
ex-smokers with or without the ICS steroids were less
symptomatic, although not significantly.
The number of pack-years correlated negatively with
FENO, rZ0.55, p< 0.001, indicating that patients with
many pack-years had a significantly lower FENO. This strong
correlation was also found when separating patients
according to ICS use, patients not on ICS, rZ0.85, p<
0.007, and patients on ICS, rZ0.45, p< 0.009.
FENO levels were not significantly different in patients
receiving ICS whether they were current (28.5 [8.5e49]
ppb), ex-smokers (29 [18e63.5] ppb) or non-smokers (34.8
[22e50.8] ppb; Fig. 4, Panel B).
The highest FENO levels (94 [15.8e151] ppb) were found
in asthmatic patients current smokers and not receiving
treatment with ICS. The most ‘‘normalised’’ FENO levels
(35.3 [13.5e35.3] pp) were seen in ex-smokers.
A weak, but significant, correlation was found between
total symptom score and the FENO levels expressed as the
difference between the actual FENO values and normal
mean FENO (16 ppb), as ‘‘the goal to be achieved’’ values
(Fig. 1, Panel C).
Figure 3 FENO according to the patients severity and their treatment with inhaled corticosteroids (Panel A), and symptoms
(Panel B).
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This study has demonstrated that FENO measurements
performed with a new hand-held monitoring device are
reproducible, simple and feasible in General Practice in
the majority of patients of different age and asthma
severity. We have also shown an overall reducing effect
of ICS on FENO regardless of the smoking habit of the
patients. Finally, we found that an high percentage of
patients with different severities of asthma and regardless
of their treatment with ICS and current smoking habit
(current and/or ex-smokers) had highly elevated FENO
values, suggesting that their current therapy was possibly
insufficient to control the underlying degree of airway
inflammation and asthma symptoms.Reproducibility and feasibility of FENO
measurements by a hand-held
device in general practice
Recently, standardised FENO measurements made in the hos-
pital laboratory in a large group of healthy and asthmatic
subjects both adults and children with the new hand-held
electrochemical-based device demonstrated a similar high
repeatability (1.2 ppb) and clinically acceptable agreement
with a stationary chemiluminescence-based device.9 As the
duration of the study visit in this study was not limited,Figure 4 FENO levels in patients with asthma according to their
habit (Panel B).patients were given the opportunity to do six tests under
guidance of a clinical personnel in order to obtain at least
three approved FENO measurements.
As we conducted our study in General Practice, limited
time reflecting the ‘‘real life situation’’ was given to
perform exhaled FENO tests in duplicate in line with the
current NO guidelines for stationary NO devices.10 High
reproducibility (ICC> 0.90 in all age groups) and very low
intra-subject variability of FENO measurements (8.7%)
underlies the great advantage of this hand-held NO device
in primary care.
High simplicity of the standardised FENO measurements
by NIOX MINO in General Practice has played a major role
in obtaining of 78% success rate in our study which was
similar to the rate of 84% when the same device was used
in both adults and children.9 It can be expected that as
soon as a patient’s individual FENO values are established
over several consecutive GP visits, a single valid FENO test
can be sufficient when using the hand-held device.
According to our data, more advanced age (above 61
years) and low actual FEV1 volume (below 1.5 L), not
asthma symptoms may have some limitations towards the
ability of patients to perform the standardised FENO test.
Correlation of the FENO levels with lung function
The significant, although weak, positive correlations that
were found between FENO levels and FEV1 results may betreatment with inhaled corticosteroids (Panel A) and smoking
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study in comparison with mild asthmatics only, when no
correlations were found between FENO and total asthma
symptoms8 or quality of life.13
More interestingly, multiple stepwise forward regression
analysis on mean FENO revealed that FEV1 (% pred.) was the
only significant predictor of the FENO levels in our patients.
This may help to introduce simple and practical guidelines
for the FENO measurement to be used together with basic
spirometry to provide complementary information for
clinical management of asthma in GP.
In future, it would be interesting to compare FENO results
with peak expiratory flow measurements which is the most
used test for the management of asthmatic patients in
General Practice. As daily measurement of FENO becomes
of wider clinical use it will be necessary to evaluate FENO
changes over time in comparison with PEF variability.
FENO in monitoring of asthma control
That patients, especially with more severe asthma, who
were not taking steroids around the time of their visit to the
GP do have significantly elevated FENO levels is well
documented in the literature. However, the degree of
FENO elevation from ‘‘the normal range’’ and regardless
of their severity in patients who were treated with ICS
was unexpectedly high.
We agree that FENO levels measured when asthma is
stable may be regarded as the baseline reference point
for individual patients against which subsequent measure-
ments are weighed. As the majority of our patients with
elevated FENO levels had a certain number and intensity
of asthma symptoms, it is reasonable to suggest that these
asthma patients were undertreated.
Undertreatment of asthma patients revealed by out-
come measures, including disease severity, lung function,
medication use, compliance, has been found in 71e74% of
patients, as this recent randomized, 3-year, longitudinal
study in 472 patients with asthma has reported.15 It can be
argued that high levels of FENO in our patients treated with
ICS may be, at least partially, ‘‘self-inflicted’’ due to their
poor compliance, which has been reported in 41% 16,580
asthma patients.16
Furthermore, potential undertreatment of our patients
may be also reflected by the fact that the majority of them
had a substantial number of asthma symptoms and by the
correlation between the ‘‘excessive FENO levels’’ and total
asthma symptoms regardless of their smoking habit and the
use of ICS.
‘‘Combined effect’’ of ICS and smoking
on FENO levels in asthma
There are three important issues related to combination of
smoking and treatment with ICS.
Firstly, cigarette smoking is common in asthmatic
patients. Thus, a combination of treatment with ICS and
smoking history (current or past) is bound to be a common
situation in day-to-day clinical practice. Indeed, 43% of our
asthmatic patients receiving treatment with ICS were
current (14%) or ex-smokers (29%).Recently, a large population study revealed a high
prevalence of current smokers (31.5%) vs. ex-smokers
(2.5%) amongst 611 young (mean age 20 years) men with
asthma.17 Most of the smoking asthmatics had mild (58.9%)
asthma. The prevalence of smoking asthmatics might have
been even higher as 7% claimed that they did not smoke
but their carbon monoxide (CO) concentration in exhaled
air was 10 ppm or higher suggesting the opposite.17
Distribution of current (22%) and ex-smokers (34%) in our
study is a reflection of more advanced age in our population
of asthmatics (mean age 53 years).
Secondly, a suppressive effect of smoking18 and ICS19,20
on FENO levels is well established.
21 Acute smoking, in most
cases, further reduces FENO,
18,22 although there are reports
suggesting the opposite effect.23 Both of these effects last
no longer than 15e30 min and can be ignored by simply
asking the patient on the time of the last cigarette and
not making FENO measurement earlier than 30 min after
that.
Thirdly, cigarette smoking aggravates the pathophysiol-
ogy of asthma,24 affects an already accelerated decline in
lung function in asthma25 and makes treatment with
corticosteroids less effective in smoking asthmatics.26
In our population, an overall reducing effect of ICS on
FENO of patients regardless of their smoking habit was
significant compared with an overall effect of smoking on
FENO in patients regardless of their treatment. This may
suggest that treatment with ICS is the major and far more
important factor to be considered when FENO is used to
monitor asthma in GP. In fact, no correlation between the
FENO levels and total symptoms in patients either treated
or not treated with ICS was found.
Although there was only very small and not significant
tendency towards higher FENO levels in ex-smokers, the
dominant suppressive effect of ICS use made the FENO levels
almost equal in all asthmatic subjects, irrespective of their
smoking habit. Interestingly, the FENO levels were the
highest in current asthmatic smokers not on ICS, suggesting
that pro-inflammatory ‘‘FENO rising effect’’ of asthma over-
laps the suppressive effect of cigarette smoking on FENO.
The fact that all our patients regardless of their smoking
history and despite regular treatment with ICS have
demonstrated abnormally high FENO values may suggest
that the dose of ICS was inadequately low. This may be
further confirmed that the majority of the patients were
symptomatic with the FENO levels, expressed as the
difference between the actual and ‘‘normal FENO’’
8 were
significantly related to their total asthma symptoms inde-
pendently of their smoking habit or treatment with ICS.
Smoking history expressed in pack-years has no de-
finitive influence on the FENO in patients treated with ICS,
but there is a tendency towards the lower FENO levels in
asthma patients with higher pack-years of smoking history.
The latter is much stronger in non-asthmatic smokers.18
Smoking cessation is associated with an increase in
exhaled NO, although NO levels remain lower than in non-
smokers.27
Limitations of study and potential sources of bias
There are limits to generalising the data from this study to
all those with asthma in primary care.
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patients who underwent FENO measurements were under-
treated was based on three facts: (a) their highly elevated
FENO levels (>35 ppb) that according to recent paper by
Taylor et al.14 suggest an intermediate level of airway
inflammation and if patients are symptomatic, the follow-
ing reasons are to be considered e possible inadequate
ICS treatment (1), poor compliance (2), poor inhaler
technique; (b) high FENO levels were registered in parallel
with a certain number of asthma symptoms; (b) asthma
patients are often undertreated in General Practice.16
Besides, it has been shown that in a population of
asthmatic patients with different severities of disease
a high percentage of patients with FENO values above
35 ppb were on corticosteroids, thus suggesting that in
a large number of patients the current therapy is not
sufficient to control the underlying airway inflammation
and needs to be improved.
On the other hand, we can be criticised that by relying,
mostly, on high FENO levels obtained by a hand-held device
we can be misled by its different accuracy, as it is based on
an electrochemical technology and most of the current
FENO published data are based on the FENO measurements
made with more analytically advanced chemiluminescence
technology.8
First of all, both these instruments are now cleared for
clinical use in Europe and NIOX has also been cleared by the
US Food and Drug Administration. Secondly, in a large group
of 71 healthy and asthmatic patients (nZ 71) it has been
shown that the overall mean values for the stationary sys-
tem (NIOX) and the hand-held device (NIOX MINO) were
26.5 24.2 ppb and 27.5 23.2 ppb, respectively, and the
reliability coefficient was high (rZ 0.97) when comparing
the individual mean values in the two devices.9 The
BlandeAltman plot not only showed agreement between
the NIOX and the NIOX MINO when comparing the mean of
three valid FENO measurements, but also demonstrated
that the median of the intra-subject FENO difference was
1.2 [3.3, 0.8] ppb, suggesting that the NIOX MINO gave
FENO readings that were generally slightly higher than the
FENO measurements obtained using the NIOX. This indicates
that for 95% of all subjects the difference between FENO
readings in NIOX and NIOX MINO is expected to lie in the
interval [9.8, 8.0] ppb.9
Close agreement between the FENOmeasurements byNIOX
MINOat homeandNIOX in the clinic (rZ 0.97) and acceptable
coefficient of variation of the FENO by NIOX MINO at home
(11%) has been recently demonstrated in children.28
On the other hand, the same authors have demonstrated
that although the measurements exhibited a high correla-
tion (rZ 0.977) independent of level (BlandeAltman plot),
FENO (NIOX MINO) was significantly higher than FENO (NIOX;
30 ppb vs. 26 ppb, pZ .004), suggesting that this can result
in a difference on 7.5 ppb, based solely on instrumental
variation.28
However, in our study, high FENO levels in potentially
undertreated asthmatics were well above ‘‘the 7.5 ppb in-
accuracy’’ and may be, therefore, a true reflection of their
current state of asthma management in General Practice.
Another limitation of this study is that some of our non-
smokers, especially with very low levels of FENO were, in
fact, current or passive smokers. As we did not measuretheir exhaled CO levels, which in fact would be valuable
and simple addition to the similar studies in primary care,
we cannot exclude this possibility. If this were even
partially true, the overall FENO levels would have been
even lower, not higher. Therefore, it is more likely that
elevated FENO levels in our asthma patients were due to
their undertreatment, rather anything else.
Conclusion
Asthmamanagement in primary care is in need of translational
research, forexample theuseofFENOmeasurementas a simple
test to monitor airway inflammation in General Practice.
FENO measurements using the new hand-held device in
General Practice are feasible and reproducible, and the
manoeuvre is well accepted by the majority of asthmatic
patients. The analysis of FENO values in our population
suggests that a significant percentage of patients on therapy
with inhaled corticosteroids have high FENO, likely reflecting
an underlining inflammation that may request an adjustment
of the current treatment. Moreover, our results suggest that
treatment with ICS is the major and far more important
factor to be considered when FENO is used to monitor asthma
in GP, regardless of the smoking habit of patients.
We agree with Price and Thomas29 that current asthma
guidelines are a good starting point to direct asthma
management, but have practical limitations in primary
care. Therefore, a focus on asthma control combined with
novel simple methods of its assessment, i.e. FENO measure-
ments in GP settings, to direct patient-focused care should
be priorities for primary care asthma guideline translation
and management activities.
Conflict of interest
Torre O, Olivieri D, Barnes PJ have no conflict of interest.
Kharitonov SA is a consultantfor Aerocrine.Acknowledgement
We would like to thank clinical research nurses Ms Lynda
Walker and Ms Angela Spenser for their technical help with
the FENO measurements.
References
1. Kharitonov SA, Barnes PJ. Exhaled markers of pulmonary
disease. Am J Respir Crit Care Med 2001;163(7):1693e722.
2. Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G,
Jackson P, et al. Diagnosing asthma: comparisons between
exhaled nitric oxide measurements and conventional tests.
Am J Respir Crit Care Med 2004;169(4):473e8.
3. Kharitonov SA, Donnelly LE, Montuschi P, Corradi M, Collins JV,
Barnes PJ. Dose-dependent onset and cessation of action of
inhaled budesonide on exhaled nitric oxide and symptoms in
mild asthma. Thorax 2002;57(10):889e96.
4. Stirling RG, Kharitonov SA, Campbell D, Robinson D, Durham SR,
Chung KF, et al. Exhaled NO is elevated in difficult asthma and
correlateswith symptoms and disease severity despite treatment
with oral and inhaled corticosteroids. Thorax 1998;53:1030e4.
1424 O. Torre et al.5. Jones SL, Kittelson J, Cowan JO, Flannery EM, Hancox RJ,
McLachlan CR, et al. The predictive value of exhaled nitric
oxide measurements in assessing changes in asthma control.
Am J Respir Crit Care Med 2001;164(5):738e43.
6. Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the
dose of inhaled steroid affect exhaled nitric oxide levels in
asthmatic patients. Eur Respir J 1996;9:196e201.
7. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use
of exhaled nitric oxide measurements to guide treatment in
chronic asthma. N Engl J Med 2005;352(21):2163e73.
8. Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Repro-
ducibility of exhaled nitric oxide measurements in healthy
and asthmatic adults and children. Eur Respir J 2003;21(3):
433e8.
9. Alving K, Janson C, Nordvall L. Performance of a new hand-held
device for exhaled nitric oxide measurement in adults and
children. Respir Res 2006;7(1):67.
10. ATS/ERS recommendations for standardized procedures for the
online and offline measurement of exhaled lower respiratory
nitric oxide and nasal nitric oxide. Am J Respir Crit Care Med
2005;171(8):912e30.
11. GINA. Revised 2006. <www.ginasthma.org>, 1e209. 2006. Ref
Type: Generic.
12. Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K.
Height, age, and atopy are associated with fraction of exhaled
nitric oxide in a large adult general population sample. Chest
2006;130(5):1319e25.
13. Ehrs PO, Sundblad BM, Larsson K. Quality of life and inflamma-
tory markers in mild asthma. Chest 2006;129(3):624e31.
14. Taylor DR, Pijnenburg MW, Smith AD, de Jongste JC. Exhaled
nitric oxide measurements: clinical application and interpreta-
tion. Thorax 2006;61(9):817e27.
15. Backer V, Nepper-Christensen S, Nolte H. Quality of care in pa-
tients with asthma and rhinitis treated by respiratory specialists
and primary care physicians: a 3-year randomized and prospec-
tive follow-up study. Ann Allergy Asthma Immunol 2006;97(4):
490e6.
16. Godard P, Huas D, Sohier B, Pribil C, Boucot I. Asthma control in
general practice: a cross-sectional survey of 16,580 patients.
Presse Med 2005;34(19 Pt 1):1351e7.17. de Granda-Orive JI, Escobar JA, Gutierrez T, Albiach JM,
Saez R, Rodero A, et al. Smoking-related attitudes, character-
istics, and opinions in a group of young men with asthma. Mil
Med 2001;166(11):959e65.
18. Kharitonov SA, Robbins RA, Yates D, Keatings V, Barnes PJ.
Acute and chronic effects of cigarette smoking on exhaled
nitric oxide. Am J Respir Crit Care Med 1995;152(2):609e12.
19. Kharitonov SA, Logan-Sinclair RB, Busset CM, Shinebourne EA.
Peak expiratory nitric oxide differences in men and women: re-
lation to the menstrual cycle. British Heart J 1994;72:243e5.
20. Kharitonov SA, Yates DH, Barnes PJ. Inhaled glucocorticoids
decrease nitric oxide in exhaled air of asthmatic patients.
Am J Respir Crit Care Med 1996;153(1):454e7.
21. Kharitonov SA. Exhaled markers of inflammatory lung diseases:
ready for routine monitoring? Swiss Med Wkly 2004;134(13-14):
175e92.
22. Robbins RA, Floreani AA, Von Essen SG, Sisson JH, Hill GE,
Rubinstein I, et al. Measurement of exhaled nitric oxide by three
different techniques.AmJRespirCritCareMed1996;153:1631e5.
23. Chambers DC, Tunnicliffe WS, Ayres JG. Acute inhalation of
cigarette smoke increases lower respiratory tract nitric oxide
concentrations. Thorax 1998;53(8):677e9.
24. Chalmers GW, MacLeod KJ, Thomson L, Little SA, McSharry C,
Thomson NC. Smoking and airway inflammation in patients
with mild asthma. Chest 2001;120(6):1917e22.
25. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year
follow-up study of ventilatory function in adults with asthma.
N Engl J Med 1998;339(17):1194e200.
26. Chaudhuri R, Livingston E, McMahon AD, Thomson L,
Borland W, Thomson NC. Cigarette smoking impairs the
therapeutic response to oral corticosteroids in chronic asthma.
Am J Respir Crit Care Med 2003;168(11):1308e11.
27. Robbins RA, Millatmal T, Lassi K, Rennard S, Daughton D. Smok-
ing cessation is associated with an increase in exhaled nitric
oxide. Chest 1997;112(2):313e8.
28. VahlkvistS,SindingM,SkamstrupK,BisgaardH.Dailyhomemeasure-
ments of exhaled nitric oxide in asthmatic children during natural
birch pollen exposure. J Allergy Clin Immunol 2006;117(6):1272e6.
29. Price D, Thomas M. Breaking new ground: challenging existing
asthma guidelines. BMC Pulm Med 2006;6(Suppl. 1):S6.
